Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms by Site 3Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Digestive System Neoplasms 2Digestive System Diseases 2Colorectal Neoplasms 2Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Previously Treated Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Pancreatic Diseases 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Colonic Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Bronchial Neoplasms 1Adenocarcinoma 1

Interventions

Musculoskeletal Manipulations 2Gemcitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2napabucasin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Endocrine System Diseases × napabucasin × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡